ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

By sjmartinez • October 31, 2024

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak SU, Paredes R, Parmar M, Peltan ID, Proschan M, Shotwell MS, Vock DM, Yokum T, Adam SJ. ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic. J Clin Transl Sci. 2024 Oct 15;8(1):e151. doi: 10.1017/cts.2024.1. PMID: 39478775; PMCID: PMC11523015.

Tags: ACTIV, Clinical Trial, covid-19, design, Infectious Diseases, lessons, Publications

Human antibody repertoire among kidney donors with and without HIV

Zhu X, Morgenlander WR, Brown DM, Eby Y, Morsheimer M, Odim J, Bagnasco SM, Rana MM, Florman SS, Friedman-Moraco RJ, Stock PG, Gilbert AJ, Mehta[...]

Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections

Mackow NA, Shao W, Ge L, Komarow L, Jiang J, Boutzoukas A, Chen L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade[...]

Immunomodulation in the Treatment of Disseminated Coccidioidomycosis

Stephens AV, Thauland TJ, Whitehill GD, Garcia-Lloret MI, Butte MJ. Immunomodulation in the Treatment of Disseminated Coccidioidomycosis. Clin Infect Dis. 2026 Mar 4:ciag036. doi: 10.1093/cid/ciag036.[...]